Abstract
To determine the usefulness of recognizing the different morphologic patterns of chronic active liver disease (CALD), we compared clinical and biochemical features as well as responses to treatment in 32 patients with chronic active hepatitis (CAH); 36 with subacute hepatitis and bridging necrosis (SHB); 30 with subacute hepatitis and multilobular necrosis (SHMN); and 30 with cirrhosis and active hepatitis (Cirrh). The morphological lesions did not correlate with clinical or etiologic features. Patients with CAH had less severe biochemical abnormalities, entered remission more often, and failed to respond to treatment less frequently than those with SHMN or Cirrh. SHB and SHMN resembled each other in many regards and showed greater functional changes than CAH. Cirrhosis developed more often after SHMN than CAH and was associated with a poorer prognosis than CAH. Serial liver biopsies revealed all possible histologic transitions, with reduction of inflammation usually occurring in patients treated with steroids and extension of inflammation being more frequent in those not receiving these drugs. CAH, SHB, SHMN, and Cirrh, therefore, reflect the degree and extent of disease activity at any given time in CALD, rather than representing different conditions. Identification of the initial morphologic lesion is helpful because of differences in prognosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nomenclature, Diagnostic Criteria, and Diagnostic Methodology for Diseases of the Liver and Biliary Tract. Fogarty International Proc., No. 22, U.S. Government Printing Office. 1976, pp. 1–11
Desmet V: Chronic hepatitis (including primary biliary cirrhosis), The Liver. Baltimore, Williams & Wilkins, 1972, pp 286–341
de Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uehlinger E, Wepler W: A classification of chronic hepatitis. Lancet 2:626–628, 1968
Klatskin G: Subacute hepatic necrosis and postnecrotic cirrhosis due to anicteric infections with the hepatitis virus. Am J Med 25:333–358, 1958
Boyer JL, Klatskin G: Pattern of necrosis in acute viral hepatitis. Prognostic value of bridging (subacute hepatic necrosis). N Engl J Med 283:1063–1071, 1970
Ware AJ, Eigenbrodt EH, Combes B: Prognostic significance of subacute hepatic necrosis in acute hepatitis. Gastroenterology 68:519–524, 1975
Bjorneboe M, Raaschou F: The pathology of subchronic atrophy of the liver. Acta Med Scand Suppl 233-236:41–62, 1949–1950
Tisdale WA: Subacute hepatitis. N Engl J Med 268:85–89, 1963
Cook CG, Mulligan R, Sherlock S: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. QJ Med 40:159–185, 1971
Murray-Lyon IM, Stern RB, Williams R: Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1:735–737, 1973
Geall MG, Schoenfield LJ, Summerskill WHJ: Classification and treatment of chronic active liver disease. Gastroenterology 55:724–729, 1968
Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ: Clinical, biochemical and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 63:820–833, 1972
Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WHJ: Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 16:1082–1086, 1971
Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ: Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 3:183–198, 1972
Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH: Prednisone for chronic active liver disease: Dose titration, standard dose and combination with azathioprine compared. Gut 16:876–883, 1975
Schalm SW, Summerskill WHJ, Gitnick GL, Elveback, LR: Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis Bs antigen. Gut 17:781–786, 1976
Author information
Authors and Affiliations
Additional information
Supported in part by Research Grant AM-6908 and Training Grant AM-5259 from the U.S. Public Health Service, and a Grant-in-Aid from Burroughs Wellcome, Inc.
Rights and permissions
About this article
Cite this article
Schalm, S.W., Korman, M.G., Summerskill, W.H.J. et al. Severe chronic active liver disease. Digest Dis Sci 22, 973–980 (1977). https://doi.org/10.1007/BF01076196
Issue Date:
DOI: https://doi.org/10.1007/BF01076196